Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare
Advanced non-small cell lung cancer (advanced NSCLC)
Kirsten rat sarcoma homolog mutations (KRAS mutations)
immune checkpoint inhibitor (ICI)
rare KRAS mutations
survival benefit
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
27
04
2024
accepted:
12
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
ppublish
Résumé
Kirsten rat sarcoma homolog ( Our retrospective study involved 240 advanced NSCLC patients with The median follow-up time was 36.5 months (range, 30.8-42.1 months) and the median OS was 9.7 months (range, 7.6-11.8 months). Of the 240 patients evaluated, 130 (54.2%) received chemotherapy and 110 (45.8%) received ICI-based treatment. Among the patients who received chemotherapy, patients with rare Despite having potential survival disadvantage compared with other NSCLC patients, rare KRAS-mutant patients (other than G12A, C, D, V) could benefit specifically from ICI-based therapy and survival outcomes are correlated with PD-L1 expression.
Sections du résumé
Background
UNASSIGNED
Kirsten rat sarcoma homolog (
Methods
UNASSIGNED
Our retrospective study involved 240 advanced NSCLC patients with
Results
UNASSIGNED
The median follow-up time was 36.5 months (range, 30.8-42.1 months) and the median OS was 9.7 months (range, 7.6-11.8 months). Of the 240 patients evaluated, 130 (54.2%) received chemotherapy and 110 (45.8%) received ICI-based treatment. Among the patients who received chemotherapy, patients with rare
Conclusions
UNASSIGNED
Despite having potential survival disadvantage compared with other NSCLC patients, rare KRAS-mutant patients (other than G12A, C, D, V) could benefit specifically from ICI-based therapy and survival outcomes are correlated with PD-L1 expression.
Identifiants
pubmed: 39118889
doi: 10.21037/tlcr-24-372
pii: tlcr-13-07-1672
pmc: PMC11304142
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1672-1684Informations de copyright
2024 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-372/coif). H.H. received grants or contracts from BMS, Lilly Oncology, Roche Diagnostics, BillionToOne; consulting fees from Mirati, Janssen, Astrazeneca, Regeneron, BMS, Guardant, Foundation Medicine, Merck, Regeneron; payment or honoraria from Amgen, Mirati, Foundation Medicine, Janssen, Astrazeneca, EMD Serono, Merck, Regeneron. F.F. serves as the Advisory board for MSD laboratory. The other authors have no conflicts of interest to declare.